Ac immune announces late-breaker presentation by genentech at ctad on phase 2 lauriet study of semorinemab in mild-to-moderate alzheimer's disease

Analysis of the broader mitt population is consistent with the previously reported success in meeting one of the two co-primary endpoints (adas-cog11) with statistically significant reduction in the rate of cognitive decline vs. placebo

ACIU Ratings Summary

ACIU Quant Ranking